TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY

用单克隆抗体靶向和治疗肿瘤

• 批准号: 3175432
• 负责人: Tsann Ming Chu
• 金额: $ 21.41万
• 依托单位: ROSWELL PARK CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-08-15 至 1991-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3175432
• 关键词: antibody specificity; bone marrow; bone marrow neoplasms; breast neoplasms; cancer registry /resource; carcinoma; combination cancer therapy; doxorubicin; histopathology; human therapy evaluation; human tissue; metal complex; metastasis; mixed tissue /cell culture; molecular oncology; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer remission /regression; neoplasm /cancer transplantation; ovary neoplasms; radioimmunoassay; radiotracer; tumor antigens; xenotransplantation

Monoclonal antibody F36/22 (1gG/3, recognizes a glycoprotein with Mr of 7001000K) has been shown immunohistochemically to be reactive with all human common epithelial, ovarian cancers, while normal ovary expresses no detectable level of immunostain. Human exfoliated ovarian tumor cells are usually disseminating throughout the entire peritoneal cavity, and represent an ideal target for therapeutic manipulation in a confined compartment. A recently available human ovarian carcinoma xenograft in female athymic mice, NIH:OVCAR-3, expresses antigen recognized by monoclonal antibody F36/22 and resembles the human disease by producing ascites and intra-abdominal carcinomatosis. Using monoclonal antibody F36/22 as the probe and NIH:OVCAR-3 as the in vivo model, we will develop and evaluate effective radioimmunotherapy for the targeting and elimination of peritoneal ovarian tumor seedings. Adriamycin, a commonly used cytotoxic agent in ovarian cancer, will be conjugated to monoclonal antibody F36/22 for intracavity immunochemotherapy of ovarian tumor. Effectiveness of both therapies will be potentiated by biological response modifiers. The proposed approaches to the use of a unique monoclonal antibody in targeting and therapy of ovarian cancer in a confined cavity compartment with little or no communication with other body compartments will generate defined and useful preclinical information.

单克隆抗体F36/22（1gG/3，识别糖蛋白 与7001000 K的先生）已被证明化学 与所有人类常见的上皮癌、卵巢癌反应， 而正常卵巢则不表达可检测水平的免疫染色。 人卵巢脱落的肿瘤细胞通常是播散性的 在整个腹膜腔，并代表一个理想的 用于在封闭隔室中进行治疗操作的目标。 一种最近可用的人卵巢癌异种移植物， 雌性无胸腺小鼠，NIH：OVCAR-3，表达抗原 被单克隆抗体F36/22识别，并类似于 人类疾病通过产生腹水和腹腔内 癌病 以单克隆抗体F36/22为探针 和NIH：OVCAR-3作为体内模型，我们将开发和 评估有效的放射免疫治疗的靶向和 腹腔卵巢肿瘤切除。 阿霉素，a 卵巢癌中常用的细胞毒性剂，将是 与单克隆抗体F36/22偶联，用于腔内 卵巢肿瘤免疫化疗 两者的有效性 生物反应调节剂将增强治疗。 使用独特的单克隆抗体的建议方法 抗体在卵巢癌靶向治疗中的应用 腔室，很少或没有与其他腔室连通 身体隔室将产生定义的和有用的临床前 信息.